Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles by Brandon G. Shutty
Based on 3 articles published since 2008
||||

Between 2008 and 2019, Brandon Shutty wrote the following 3 articles about Psoriasis.
 
+ Citations + Abstracts
1 Review Apremilast as a treatment for psoriasis. 2012

Shutty, Brandon / West, Cameron / Pellerin, Megan / Feldman, Steven. ·Wake Forest University Health Sciences, Department of Dermatology, Center for Dermatology Research, Medical Center Boulevard, Winston-Salem, NC 27157-1071, USA. ·Expert Opin Pharmacother · Pubmed #22712800.

ABSTRACT: INTRODUCTION: Psoriasis is a common skin disorder characterized by chronic inflammatory lesions that are frequently vexing for patients and difficult for physicians to treat. Although multiple therapeutic options are available, all have limitations. Topical preparations have issues with patient adherence, as compared to oral routes of administration. Currently available oral medications, such as methotrexate, possess unfavorable toxicity profiles that limit use. There is a large unmet need for an effective, safe oral treatment for psoriasis. Apremilast is an oral medication that inhibits the activity of multiple inflammatory markers involved in the pathogenesis of psoriasis. AREAS COVERED: The present review article presents the pharmacokinetic properties of apremilast, as well as available preliminary pre-clinical and clinical trial data, and gives an overview of its safety and efficacy. EXPERT OPINION: Apremilast has been well tolerated in phase I and II clinical trials. It has favorable safety and toxicity profiles at doses that are also effective for the treatment of plaque psoriasis. Phase III clinical trials are currently underway and will better elucidate appropriate dosing of apremilast and further illuminate its side effect profile. In future studies, a comparison of apremilast to other psoriasis medications administered through different routes would be beneficial, to document whether patient adherence is better with an oral medication. Depending on the price of the agent, efficacy and perhaps most importantly its safety profile, apremilast may fill a key need as a safe, first-line oral treatment for patients with psoriasis.

2 Article Sleep disturbances in psoriasis. 2013

Shutty, Brandon G / West, Cameron / Huang, Karen E / Landis, Erin / Dabade, Tushar / Browder, Betsy / O'Neill, Jenna / Kinney, Megan A / Feneran, Ashley N / Taylor, Sarah / Yentzer, Brad / McCall, W Vaughn / Fleischer, Alan B / Feldman, Steven R. ·Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston Salem, NC, USA. ·Dermatol Online J · Pubmed #23374943.

ABSTRACT: BACKGROUND: Psoriasis negatively impacts sleep, but the factors that cause this sleep disturbance are not well characterized. PURPOSE: To assess sleep quality in subjects with psoriasis. METHODS: 35 outpatients diagnosed with chronic plaque psoriasis affecting at least 10 percent BSA and 44 controls completed the Pittsburgh Sleep Quality Index, Patient Health Questionnaire, Itch Severity Scale, Insomnia Severity Index, and Epworth Sleepiness Scale. For multiple testing, alpha was set at 0.008. RESULTS: Adjusting for age, BMI, and gender, patients with psoriasis had 4.3 times the odds to score in a higher insomnia category (OR 95% CI: 1.7, 11.2; p=0.01), a trend toward experiencing "poor sleep" (p=0.04), and no difference in odds to be "sleepy" (p=0.83). Patients with psoriasis had greater itch than those without psoriasis (mean ISS 8.5 vs. 2.0; p<0.0001). When adjusting for age, BMI, gender, and depression, those with psoriasis were not more likely to experience poor sleep quality (p=0.25), nor to score in a higher insomnia category (p=0.20) or be more "sleepy" (p=0.53). CONCLUSIONS: Patients with psoriasis suffer from sleep disturbances and pruritus more than those without psoriasis. Although sleep disturbances are more prevalent, this may be secondary to depression rather than related to a direct effect of psoriasis.

3 Minor The safety of immunosuppressants in the treatment of psoriasis patients: is there concern regarding those with familial lymphoproliferative disease? 2013

Shutty, Brandon G / Hogan, Daniel J. ·Nova Southeastern University, Largo Medical Center, Largo, FL, USA. ·Dermatol Online J · Pubmed #23374957.

ABSTRACT: Immunosuppressant drugs may increase the risk of lymphoproliferative disease (LPD) states, and additionally, the diagnosis of psoriasis may predispose to lymphoma. It is important to educate patients regarding the side effects of any treatment regimen. A positive family history of LPD disease may increase the risk of personal acquisition of LPD disease in those patients with psoriasis additionally making use of immunosuppressant therapy, such as the biologics. It is currently recommended to employ caution in those being treated with biologics who carry a high risk of developing malignancy. Those with a positive family history may fit into this category.